BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Panés J, Gomollón F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007;67:2511-37. [PMID: 18034589 DOI: 10.2165/00003495-200767170-00005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Review of Clinical Immunology 2014;6:659-66. [DOI: 10.1586/eci.10.46] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
2 Santín Cerezales M, Benítez JD. Diagnosis of tuberculosis infection using interferon-γ-based assays. Enfermedades Infecciosas y Microbiología Clínica 2011;29:26-33. [DOI: 10.1016/s0213-005x(11)70015-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
3 Gomollón F, Gisbert JP. [Must immunomodulators be added to biological treatment in inflammatory bowel disease?]. Gastroenterol Hepatol 2010;33:43-53. [PMID: 19616870 DOI: 10.1016/j.gastrohep.2009.03.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Goulart RA, Barbalho SM, Gasparini RG, de Carvalho AC. Facing Terminal Ileitis: Going Beyond Crohn's Disease. Gastroenterology Res 2016;9:1-9. [PMID: 27785317 DOI: 10.14740/gr698w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
5 Gomollón F, Gisbert JP, Gassull M&. Crohnology: A tale of time and times and inflammatory bowel diseases. World J Gastroenterol 2008; 14(36): 5489-5490 [PMID: 18810763 DOI: 10.3748/wjg.14.5489] [Reference Citation Analysis]
6 Kostoff RN. Literature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease. Scientometrics 2014;100:623-57. [DOI: 10.1007/s11192-014-1298-3] [Cited by in Crossref: 12] [Article Influence: 1.5] [Reference Citation Analysis]
7 Hu G, Agarwal P. Human disease-drug network based on genomic expression profiles. PLoS One 2009;4:e6536. [PMID: 19657382 DOI: 10.1371/journal.pone.0006536] [Cited by in Crossref: 206] [Cited by in F6Publishing: 172] [Article Influence: 15.8] [Reference Citation Analysis]
8 Browne SK, Holland SM. Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms. Lancet Infect Dis 2010;10:875-85. [PMID: 21109174 DOI: 10.1016/S1473-3099(10)70196-1] [Cited by in Crossref: 55] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
9 Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008; 14(33): 5154-5161 [PMID: 18777592 DOI: 10.3748/wjg.14.5154] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 89] [Article Influence: 5.9] [Reference Citation Analysis]
10 Ozturk O, Koklu S, Basar O, Purnak T, Yuksel O. CROHN DISEASE PRESENTED WITH A GIANT COLONIC MASS. Gastroenterol Nurs 2016;39:235-7. [PMID: 27258465 DOI: 10.1097/SGA.0000000000000249] [Reference Citation Analysis]
11 Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010;24 Suppl 1:3-14. [PMID: 21175228 DOI: 10.2165/11586290-000000000-00000] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
12 Drago L, Nicola L, Signori V, Palazzi E, Garutti C, Spadino S, Altomare G. Dynamic QuantiFERON Response in Psoriasis Patients Taking Long-Term Biologic Therapy. Dermatol Ther (Heidelb) 2013;3:73-81. [PMID: 23888257 DOI: 10.1007/s13555-013-0020-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
13 Mir Subías A, García-López S, Sebastián Torres B, Ollero Domenche L, García Gámez A, Gomollón F. [Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease]. Gastroenterol Hepatol 2013;36:81-5. [PMID: 23218770 DOI: 10.1016/j.gastrohep.2012.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760-7. [PMID: 19174781 DOI: 10.1038/ajg.2008.88] [Cited by in Crossref: 357] [Cited by in F6Publishing: 359] [Article Influence: 27.5] [Reference Citation Analysis]
15 Holubar SD, Dozois EJ, Privitera A, Pemberton JH, Cima RR, Larson DW. Minimally invasive colectomy for Crohn’s colitis: a single institution experience. Inflamm Bowel Dis. 2010;16:1940-1946. [PMID: 20848480 DOI: 10.1002/ibd.21265] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
16 Chiappini E, de Martino M, Mangiantini F, Lionetti P. Crohn disease and mycobacterial infection in children: an intriguing relationship. J Pediatr Gastroenterol Nutr. 2009;49:550-558. [PMID: 19680150 DOI: 10.1097/mpg.0b013e3181b0f908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
17 Pollastri MP, Whitty A, Merrill JC, Tang X, Ashton TD, Amar S. Identification and characterization of kava-derived compounds mediating TNF-alpha suppression. Chem Biol Drug Des 2009;74:121-8. [PMID: 19538508 DOI: 10.1111/j.1747-0285.2009.00838.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
18 Chiodini RJ, Chamberlin WM, Sarosiek J, McCallum RW. Crohn’s disease and the mycobacterioses: a quarter century later. Causation or simple association? Crit Rev Microbiol. 2012;38:52-93. [PMID: 22242906 DOI: 10.3109/1040841x.2011.638273] [Cited by in Crossref: 100] [Cited by in F6Publishing: 48] [Article Influence: 10.0] [Reference Citation Analysis]
19 Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics. 2008;2:763-777. [PMID: 19707457 DOI: 10.2147/btt.s3292] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 0.5] [Reference Citation Analysis]
20 Smith LS, Nelson M, Dolder CR. Certolizumab pegol: a TNF-{alpha} antagonist for the treatment of moderate-to-severe Crohn's disease. Ann Pharmacother 2010;44:333-42. [PMID: 20118143 DOI: 10.1345/aph.1M314] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Tenailleau QM, Lanier C, Gower-Rousseau C, Cuny D, Deram A, Occelli F. Crohn's disease and environmental contamination: Current challenges and perspectives in exposure evaluation. Environ Pollut 2020;263:114599. [PMID: 32325248 DOI: 10.1016/j.envpol.2020.114599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
22 Guttman-Yassky E, Dhingra N, Leung DY. New era of biologic therapeutics in atopic dermatitis. Expert Opin Biol Ther 2013;13:549-61. [PMID: 23323893 DOI: 10.1517/14712598.2013.758708] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 7.6] [Reference Citation Analysis]
23 Domínguez J, Latorre I, Altet N, Mateo L, De Souza-galvão M, Ruiz-manzano J, Ausina V. IFN-γ-release assays to diagnose TB infection in the immunocompromised individual. Expert Review of Respiratory Medicine 2014;3:309-27. [DOI: 10.1586/ers.09.20] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
24 Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update: . European Journal of Gastroenterology & Hepatology 2010;22:779-86. [DOI: 10.1097/meg.0b013e328331b654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
25 Yang CL, Chik SC, Li JC, Cheung BK, Lau AS. Identification of the bioactive constituent and its mechanisms of action in mediating the anti-inflammatory effects of black cohosh and related Cimicifuga species on human primary blood macrophages. J Med Chem 2009;52:6707-15. [PMID: 19835377 DOI: 10.1021/jm9006164] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
26 Elbadry M, Nour MO, Hussien M, Ghoneem EA, Medhat MA, Shehab H, Galal S, Eltabbakh M, El-raey F, Negm M, Afify S, Abdelhamed W, Sherief A, Abdelaziz A, Abo Elkasem M, Mahrous A, Kamal G, Maher M, Abdel-hameed O, Elbasuny A, El-zayyadi I, Bassiony A, Moussa A, Bedewy E, Elfert A, El Kassas M. Clinico-Epidemiological Characteristics of Patients With Inflammatory Bowel Disease in Egypt: A Nationwide Multicenter Study. Front Med 2022;9:867293. [DOI: 10.3389/fmed.2022.867293] [Reference Citation Analysis]
27 Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut 2013;62:1288-94. [PMID: 22760005 DOI: 10.1136/gutjnl-2011-300995] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
28 Howell MD, Parker ML, Mustelin T, Ranade K. Past, present, and future for biologic intervention in atopic dermatitis. Allergy 2015;70:887-96. [PMID: 25879391 DOI: 10.1111/all.12632] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
29 Mínguez S, Latorre I, Mateo L, Lacoma A, Diaz J, Olivé A, Domínguez J. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment. Clin Rheumatol 2012;31:785-94. [DOI: 10.1007/s10067-012-1938-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ruan J, Zhou Y. Regaining normality: A grounded theory study of the illness experiences of Chinese patients living with Crohn's disease. Int J Nurs Stud 2019;93:87-96. [PMID: 30901715 DOI: 10.1016/j.ijnurstu.2019.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
31 Markel TA, Crisostomo PR, Lahm T, Novotny NM, Rescorla FJ, Tector J, Meldrum DR. Stem cells as a potential future treatment of pediatric intestinal disorders. J Pediatr Surg 2008;43:1953-63. [PMID: 18970924 DOI: 10.1016/j.jpedsurg.2008.06.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
32 Aukrust P, Sandberg WJ, Otterdal K, Vinge LE, Gullestad L, Yndestad A, Halvorsen B, Ueland T. Tumor necrosis factor superfamily molecules in acute coronary syndromes. Ann Med. 2011;43:90-103. [PMID: 21039303 DOI: 10.3109/07853890.2010.523711] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
33 Hong MK, Craig Lynch A, Bell S, Woods RJ, Keck JO, Johnston MJ, Heriot AG. Faecal diversion in the management of perianal Crohn's disease. Colorectal Dis 2011;13:171-6. [PMID: 19863597 DOI: 10.1111/j.1463-1318.2009.02092.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
34 Braña MF, Acero N, Añorbe L, Mingarro DM, Llinares F, Domínguez G. Discovering a new analogue of thalidomide which may be used as a potent modulator of TNF-α production. European Journal of Medicinal Chemistry 2009;44:3533-42. [DOI: 10.1016/j.ejmech.2009.03.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
35 Kumar A, Auron M, Aneja A, Mohr F, Jain A, Shen B. Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc. 2011;86:748-757. [PMID: 21803957 DOI: 10.4065/mcp.2011.0074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
36 Garrick V, Stenhouse E, Haddock G, Russell RK. A multidisciplinary team model of caring for patients with perianal Crohn's disease incorporating a literature review, topical therapy and personal practice. Frontline Gastroenterol 2013;4:152-60. [PMID: 28839719 DOI: 10.1136/flgastro-2012-100160] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
37 Mahdi BM. Role of HLA typing on Crohn's disease pathogenesis. Ann Med Surg (Lond) 2015;4:248-53. [PMID: 26288728 DOI: 10.1016/j.amsu.2015.07.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
38 Etchevers MJ, Ordás I, Ricart E. Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohnʼs Disease: A Practical Approach. Drugs 2010;70:109-20. [DOI: 10.2165/11533700-000000000-00000] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
39 Bandzar S, Gupta S, Platt MO. Crohn’s disease: a review of treatment options and current research. Cell Immunol. 2013;286:45-52. [PMID: 24321565 DOI: 10.1016/j.cellimm.2013.11.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
40 Uetrecht J. Immune-mediated adverse drug reactions. Chem Res Toxicol 2009;22:24-34. [PMID: 19149477 DOI: 10.1021/tx800389u] [Cited by in Crossref: 82] [Cited by in F6Publishing: 63] [Article Influence: 6.3] [Reference Citation Analysis]
41 Kim J, Griffiths MW. Emerging Pathogenic Bacteria: Mycobacterium avium subsp. paratuberculosis in Foods. Korean Journal for Food Science of Animal Resources 2011;31:147-57. [DOI: 10.5851/kosfa.2011.31.2.147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]